Clinical study on the effect and security of different doses of rosuvastatin therapy in acute coronary syndrome ;patients with diabetes

Huaqing Qu,Qiang Tang,Jinqiu Yao,XiaoLin Yan,Zhi Wang,Kun Liu

DOI: https://doi.org/10.15932/j.0253-9713.2015.4.007

2015-01-01

Abstract:Objective To investigate the effect and sefety of different doses of rosuvastatin on serum high sensitivi-ty C-reactive protein and blood lipid levels,blood glucose levels in acute coronary syndrome patients with diabetes. Meth-ods A total of 164 patients with ACS complicated with diabetes were randomly assigned into the large dosage of rosuvas-tatin (20 mg/d) group(n=82) and the routine dosage of rosuvastatin group(10 mg/d) (n=82). Serum levels of blood lipid, blood glucose ,hs-CRP, HbA1c were measured with biochemistry assay 24 hours after admission. Blood lipid level, and hs-CRP were measured 4 weeks later. All above parameter were measured 12 weeks after therapy. The difference in blood lipid levels, hs-CRP, blood glucose and HbA1c was compared between the two groups. Results Among the two groups, the levels of blood lipid decreased(P<0.05). The levels of hs-CRP decreased significantly comparing with the routine dosage of rosuvastatin group(the values of control group were(19.68±12.62)mg/L,(12.69±10.59)mg/L,(10.07± 9.63)mg/L;while the test group were(19.70 ± 12.50)mg/L,(11.23 ± 8.64)mg/L and(8.32 ± 7.59)mg/L, P<0.01;but no statistically significant differences were found in FBG and HbA1c levels between the two groups(P>0.05). Conclusion Effect of early large dosage rosuvastatin therapy on serum hs-CRP levels is better than the routine dosage and is safe in pa-tients with diabetes complicated with acute coronary syndrome. Rosuvastatin has no effect on blood glucose level.